Kymera Therapeutics (KYMR) Stock Analysis
This is a peer-relative look at Kymera Therapeutics (KYMR): its performance, risk, profitability, growth, financial strength, dividend, and valuation are each measured against its Pharmaceuticals, Biotechnology & Life Sciences peers, so every number reads in context rather than in isolation.
Company Profile
| Profile Item | KYMR |
|---|---|
| Name | Kymera Therapeutics Inc. |
| Country/Region | United States |
| GICS Sector | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology |
| GICS Sub-Industry | Biotechnology |
| Market Capitalization | 11.25 billion USD |
| Currency | USD |
| Exchange | Nasdaq |
| Listing Date | August 21, 2020 |
| Security Type | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | Current stock: KYMR | Industry group median |
|---|---|---|
| Total Return (1Y) | 131.52% | 24.62% |
| Total Return (3Y, Annualized) | 111.65% | 20.37% |
| Total Return (5Y, Annualized) | 15.68% | -4.02% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | Current stock: KYMR | Industry group median |
|---|---|---|
| Volatility (1Y, Annualized) | 62.83% | 66.36% |
| Beta (5Y) | 2.00 | 0.93 |
| Max Drawdown (5Y) | -83.27% | -80.19% |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | Current stock: KYMR | Industry group median |
|---|---|---|
| Sharpe Ratio (1Y) | 2.03 | 0.36 |
| Sortino Ratio (1Y) | 4.16 | 0.58 |
Profitability
ROE (TTM)
Kymera Therapeutics (KYMR) has negative ROE of -27.29%. That can come from trailing losses or negative book equity, so it is a warning state rather than a clean capital-efficiency measure.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
-27.29%
Group distribution
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- KYMR
- -27.29%
- Q1
- -64.05%
- Min
- -167.77%
Largest peers
- LLY
- 86.02%
- NVS
- 24.33%
- AZN
- 22.57%
- JNJ
- 20.02%
- MRK
- 5.06%
- KYMR
- -27.29%
- ABBV
- --
Net Margin (TTM)
Kymera Therapeutics (KYMR) keeps 0.00% of revenue as net profit, roughly in line with the peer group’s normal net margin range. Its full cost stack is taking a typical share of sales for the industry.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
Group distribution
- Max
- 18.05%
- Q3
- 4.78%
- KYMR
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Largest peers
- LLY
- 31.90%
- AZN
- 17.68%
- NVS
- 17.49%
- JNJ
- 16.20%
- ABBV
- 15.67%
- MRK
- 3.64%
- KYMR
- 0.00%
Operating Margin (TTM)
Kymera Therapeutics (KYMR) has negative operating margin of -396.04%. Core operations were loss-making before interest and taxes over the trailing period.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
-396.04%
Group distribution
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
- KYMR
- -396.04%
Largest peers
- LLY
- 53.66%
- ABBV
- 39.59%
- MRK
- 35.22%
- NVS
- 34.27%
- AZN
- 29.57%
- JNJ
- 25.74%
- KYMR
- -396.04%
Profitability Metrics
| Metric | Current stock: KYMR | Industry group median |
|---|---|---|
| ROE (TTM) | -27.29% | -26.66% |
| ROA (TTM) | -17.64% | -12.50% |
| Net Margin (TTM) | 0.00% | 0.00% |
| Operating Margin (TTM) | -396.04% | 0.00% |
| Gross Margin (TTM) | 0.00% | 37.87% |
Growth
Revenue Growth
Kymera Therapeutics (KYMR) grew revenue -16.70%, in the lower peer quartile. The top line is expanding more slowly than at most peers, which can reflect softer demand, lost share, or weaker pricing.
EPS Growth
No usable EPS growth is available for Kymera Therapeutics (KYMR) this period, so the earnings-momentum read is skipped.
Growth Metrics
| Metric | Current stock: KYMR | Industry group median |
|---|---|---|
| Revenue Growth (YoY) | -16.70% | 11.45% |
| Revenue Growth (3Y CAGR) | -5.74% | 9.94% |
| EPS Growth (YoY) | -- | 4.28% |
| EPS Growth (3Y CAGR) | -- | 4.17% |
Financial Strength
Current Ratio (MRQ)
Kymera Therapeutics (KYMR) has current ratio of 11.13, in the healthier middle range for its industry. The short-term asset cushion looks balanced relative to peers rather than stretched thin.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.13
Group distribution
- Max
- 25.13
- Q3
- 12.13
- KYMR
- 11.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Largest peers
- KYMR
- 11.13
- LLY
- 1.39
- MRK
- 1.35
- JNJ
- 1.02
- AZN
- 1.01
- NVS
- 0.88
- ABBV
- 0.87
Debt / Equity (MRQ)
Kymera Therapeutics (KYMR) has debt-to-equity ratio of 0.05, roughly in line with the peer group’s normal leverage range. Its mix of debt and equity looks typical for the industry.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.05
Group distribution
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- KYMR
- 0.05
- Q1
- 0.02
- Min
- 0.00
Largest peers
- NVS
- 1.29
- LLY
- 1.23
- MRK
- 1.20
- AZN
- 0.66
- JNJ
- 0.55
- KYMR
- 0.05
- ABBV
- --
Financial Strength Metrics
| Metric | Current stock: KYMR | Industry group median |
|---|---|---|
| Current Ratio (MRQ) | 11.13 | 5.52 |
| Debt / Equity (MRQ) | 0.05 | 0.15 |
| Net Debt / EBITDA | -- | 1.08 |
Dividends
Dividend Yield (TTM)
Kymera Therapeutics (KYMR) pays no dividend, leaving dividend yield at 0.00% this period. Shareholders may still receive value through reinvestment or buybacks, but there is no dividend income to compare here.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
Group distribution
- KYMR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Largest peers
- NVS
- 2.88%
- ABBV
- 2.40%
- MRK
- 2.29%
- JNJ
- 1.94%
- AZN
- 1.73%
- LLY
- 0.49%
- KYMR
- 0.00%
Dividend Payout Ratio (TTM)
Kymera Therapeutics (KYMR) paid no earnings out as dividends this period, leaving payout ratio at 0.00%. There is no dividend payout to size against earnings.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
Group distribution
- KYMR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Largest peers
- MRK
- 343.43%
- ABBV
- 117.35%
- NVS
- 90.46%
- JNJ
- 80.12%
- AZN
- 45.38%
- LLY
- 21.71%
- KYMR
- 0.00%
Dividend Metrics
| Metric | Current stock: KYMR | Industry group median |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
No usable P/E ratio is available for Kymera Therapeutics (KYMR) this period, so the trailing-earnings valuation read is skipped.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
Group distribution
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- KYMR
- --
Largest peers
- MRK
- 148.21
- ABBV
- 50.05
- LLY
- 43.95
- JNJ
- 41.92
- NVS
- 31.02
- AZN
- 26.37
- KYMR
- --
P/S Ratio (TTM)
Kymera Therapeutics (KYMR) trades at 110.00 on P/S ratio, above the industry benchmark range. The stock is being valued at an unusually rich price per dollar of trailing revenue.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
110.00
Group distribution
- KYMR
- 110.00
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
Largest peers
- KYMR
- 110.00
- LLY
- 13.95
- ABBV
- 7.80
- JNJ
- 6.69
- MRK
- 5.37
- NVS
- 5.35
- AZN
- 4.63
P/B Ratio (MRQ)
Kymera Therapeutics (KYMR) trades at 6.96 on P/B ratio, in the higher book-value quartile. The market is paying a premium to book, so stronger ROE, cleaner assets, or a better growth profile need to justify it.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.96
Group distribution
- Max
- 13.53
- KYMR
- 6.96
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Largest peers
- LLY
- 29.96
- NVS
- 8.25
- JNJ
- 8.16
- MRK
- 8.06
- KYMR
- 6.96
- AZN
- 5.59
- ABBV
- -112.34
Valuation Metrics
| Metric | Current stock: KYMR | Industry group median |
|---|---|---|
| P/E Ratio (TTM) | -- | 26.69 |
| P/S Ratio (TTM) | 110.00 | 7.30 |
| P/B Ratio (MRQ) | 6.96 | 3.25 |
| Free Cash Flow Yield (TTM) | -1.46% | -1.66% |